Daiichi Sankyo Co Ltd - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DSNKY Over the counter 2834 https://www.daiichisankyo.co.jp/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daiichi Sankyo Co Ltd - ADR

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars - May 7th, 2024 4:20 pm
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement - Apr 29th, 2024 2:26 pm
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - Apr 29th, 2024 6:00 am
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain' - Apr 25th, 2024 7:49 pm
Atossa (ATOS) Reports Positive Results From EVANGELINE Study - Apr 11th, 2024 2:10 pm
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised) - Apr 9th, 2024 3:38 am
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor - Apr 8th, 2024 4:34 pm
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors - Apr 8th, 2024 1:21 pm
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors - Apr 6th, 2024 3:10 am
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug - Apr 4th, 2024 9:36 am
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer - Apr 3rd, 2024 12:00 pm
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance - Apr 2nd, 2024 1:15 pm
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Apr 2nd, 2024 6:00 am
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer - Mar 4th, 2024 7:00 am
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues - Feb 28th, 2024 12:41 pm
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer - Feb 19th, 2024 7:00 am
Daiichi invests 1 bln eur near Munich to make precision cancer drugs - Feb 16th, 2024 2:41 pm
Q4 2023 Merck & Co Inc Earnings Call - Feb 2nd, 2024 4:56 am
AstraZeneca, Daiichi aim for first pan-tumor ADC approval - Jan 29th, 2024 10:00 am
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors - Jan 29th, 2024 7:00 am